The research results, published in the Diabetes Technology & Therapeutics journal, showed a positive clinical impact of the Control-IQ technology’s automatic correction bolusing on glucose control
The participants in the study used a Dexcom G6 continuous glucose monitoring system. (Credit: Towfiqu barbhuiya on Unsplash)
Tandem Diabetes Care, an insulin delivery and diabetes technology company, has announced a positive meta-analysis of three randomised controlled trials of its Control-IQ advanced hybrid closed-loop technology.
The research results, published in the Diabetes Technology & Therapeutics journal, showed a positive clinical impact of the Control-IQ technology’s automatic correction bolusing on glucose control.
The research was conducted on a range of ages and demographics of people having type 1 diabetes. The participants used a Dexcom G6 continuous glucose monitoring (CGM) system.
Tandem Diabetes Care said that individuals with high baseline blood sugar levels benefitted the most from the auto-bolus feature of the Control-IQ algorithm.
The automatic correction blousing is said to be an automated insulin dosing feature that is only available commercially in the t:slim X2 insulin pump, which comes with Control-IQ technology.
Tandem Diabetes Care vice president and medical director Jordan Pinsker said: “With three randomised, controlled trials completed, Control-IQ technology has the most robust data set supporting its benefits compared to any other automated insulin delivery system available today.”
In the analysis, people demonstrated an average increase in time in a range of 2.8 hours. It also showed a reduction in haemoglobin A1c in comparison to control groups in people of age 2-72 years old.
Additionally, the changes in time in range for subjects using Control-IQ technology were sustained, immediate, and observed across a range of patient characteristics.
The diabetes technology company said that 91% of the subjects in the control group used an insulin pump, some with predictive low glucose suspend technology.
The meta-analysis was funded by the US-based National Institute of Diabetes and Digestive and Kidney Diseases.
University of Virginia Centre for Diabetes Technology director Boris Kovatchev said: “All subgroups in these studies, regardless of age, ethnicity, education, or previous pump experience, benefited from Control-IQ technology.
“It is clear from these results, which are consistent with real-life data from thousands of current Control-IQ technology users, that this technology should be considered as an option for anyone living with type 1 diabetes.”
In December last year, Tandem signed an agreement to buy Switzerland-based Sigi Patch Pump developer AMF Medical.